Cornu C, Yzèbe D, Léophonte P, Gaillat J, Boissel J P, Cucherat M
Service of Clinical Pharmacology, EA643, Lyon University Hospital, Faculté de Médicine RTH Laennec, BP 8071, 69376, Cedex 08, Lyon, France.
Vaccine. 2001 Sep 14;19(32):4780-90. doi: 10.1016/s0264-410x(01)00217-1.
The use of pneumococcal polysaccharide vaccine (PPV) is low in some countries, maybe because of doubts regarding its efficacy. This meta-analysis aims at combining evidence from randomized trials of PPV assessing its efficacy in preventing Streptococcus pneumoniae related diseases in immunocompetent adults. In the fourteen trials totalling 48,837 patients retrieved, PPV prevents definite pneumococcal pneumonia by 71%, presumptive pneumococcal pneumonia by 40%, and mortality due to pneumonia by 32%, but not all-cause pneumonia or death. No preventive effect was seen in the subgroup of patients aged 55 years or more, possibly due to a lack of statistical power.
在一些国家，肺炎球菌多糖疫苗（PPV）的使用比例较低，这可能是因为对其疗效存在疑虑。这项荟萃分析旨在整合来自PPV随机试验的证据，评估其在免疫功能正常的成年人中预防肺炎链球菌相关疾病的疗效。在检索到的总计48837名患者的14项试验中，PPV可使确诊的肺炎球菌肺炎减少71%，疑似肺炎球菌肺炎减少40%，肺炎导致的死亡率降低32%，但对全因性肺炎或死亡没有预防作用。在55岁及以上的患者亚组中未观察到预防效果，这可能是由于缺乏统计学效力。
